Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994

被引:68
作者
Maloney, KW
Shuster, JJ
Murphy, S
Pullen, J
Camitta, BA
机构
[1] Midwest Childrens Canc Ctr, Dept Pediat, Milwaukee, WI 53226 USA
[2] Univ Florida, Pediat Oncol Grp, Stat Off, Gainesville, FL USA
[3] Univ Florida, Dept Stat, Gainesville, FL USA
[4] Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA
[5] Northwestern Univ, Sch Med, Childrens Mem Hosp, Dept Hematol Oncol, Chicago, IL 60611 USA
[6] Univ Mississippi, Med Ctr, Dept Pediat, Childrens Hosp, Jackson, MS 39216 USA
关键词
B-lineage ALL; T-lineage ALL; infant ALL; prognostic factors; outcome;
D O I
10.1038/sj.leu.2401965
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This paper presents the long-term results of treatment for children with acute lymphoblastic leukemia (ALL) as conducted by the Pediatric Oncology Group (POG) from 1986 to 1994. The data are presented using standard NCI/Rome risk criteria. The overall event-free survival (EFS) at 5 and 10 years were 70.9% and 67.3% for children with B-precursor ALL, 51.0% and 50.2%, far patients with T cell ALL, and 22.4% and 20.9% for infants with ALL. Concomitant biologic studies found that in B-precursor ALL a DNA index (DI) of greater than or equal to1.16 and trisomies of bath chromosomes 4 and 10 were good prognostic indicators for patients with B-precursor ALL. The traditional prognostic indicators (age and white count), DI and trisomies did not predict outcome in patients with T cell disease. Infants continued to do poorly overall despite more intensive therapy with rotating pairs of chemotherapy. We recommend continued reporting of study results using common risk criteria in order to facilitate comparisons both within and across study groups.
引用
收藏
页码:2276 / 2285
页数:10
相关论文
共 36 条
[1]   Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study [J].
Amylon, MD ;
Shuster, J ;
Pullen, J ;
Berard, C ;
Link, MP ;
Wharam, M ;
Katz, J ;
Yu, A ;
Laver, J ;
Ravindranath, Y ;
Kurtzberg, J ;
Desai, S ;
Camitta, B ;
Murphy, SB .
LEUKEMIA, 1999, 13 (03) :335-342
[2]   Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Aricò, M ;
Valsecchi, MG ;
Camitta, B ;
Schrappe, M ;
Chessells, J ;
Baruchel, A ;
Gaynon, P ;
Silverman, L ;
Janka-Schaub, G ;
Kamps, W ;
Pui, CH ;
Masera, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) :998-1006
[3]   Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL:: a pediatric oncology group study [J].
Borowitz, MJ ;
Rubnitz, J ;
Nash, M ;
Pullen, DJ ;
Camitta, B .
LEUKEMIA, 1998, 12 (11) :1764-1770
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
CRIST W, 1990, BLOOD, V76, P489
[6]  
CRIST WM, 1990, BLOOD, V76, P117
[7]  
DREYER ZE, 1998, ASCO P, V17, pA529
[8]   Therapeutic trial for infant acute lymphoblastic leukemia: The pediatric oncology group experience (POG 8493) [J].
Frankel, LS ;
Ochs, J ;
Shuster, JJ ;
Dubowy, R ;
Bowman, WP ;
HockenberryEaton, M ;
Borowitz, M ;
Carroll, AJ ;
Steuber, CP ;
Pullen, DJ .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (01) :35-42
[9]  
GOLDIE JH, 1982, CANCER TREAT REP, V66, P439
[10]  
HARRIS MB, 1992, BLOOD, V79, P3316